AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 17080767 — intervention group
Group type: COMPARATOR
Intervention: Control arm
Number of subjects: 0
Study 12742873 — intervention group
Group type: EXPERIMENTAL
Intervention: Behavioral Therapy (BT)
Number of subjects: 43
Study 12742873 — intervention group
Group type: EXPERIMENTAL
Intervention: Fluoxetine (60 mg/d)
Number of subjects: 43
Study 12742873 — intervention group
Group type: COMPARATOR
Intervention: Waiting-list (WL) control
Number of subjects: 43
Study 12742873 — intervention group
Group type: EXPERIMENTAL
Intervention: General psychopathologic and depressive symptoms
Number of subjects: 43
Study 10911766 — intervention group
Group type: EXPERIMENTAL
Intervention: 677CC/1298AA genotype
Number of subjects: 66
Study 10911766 — intervention group
Group type: EXPERIMENTAL
Intervention: 677CC/1298AC genotype
Number of subjects: 66
Study 10911766 — intervention group
Group type: EXPERIMENTAL
Intervention: 677CC/1298CC genotype
Number of subjects: 66
Study 10911766 — intervention group
Group type: EXPERIMENTAL
Intervention: 677CT/1298AC genotype
Number of subjects: 66
Study 10911766 — intervention group
Group type: EXPERIMENTAL
Intervention: 677TT and 1298CC genotypes
Number of subjects: 66
Study 8656390 — intervention group
Group type: EXPERIMENTAL
Intervention: Healon
Number of subjects: 60
Study 8656390 — intervention group
Group type: EXPERIMENTAL
Intervention: Healon GV
Number of subjects: 60
Study 1508058 — intervention group
Group type: EXPERIMENTAL
Intervention: Oestriol (E3) 0.5 mg administered intravaginally daily for 2 weeks, then once or twice weekly for 4 weeks as maintenance dose.
Number of subjects: 40
Study 1508058 — intervention group
Group type: EXPERIMENTAL
Intervention: Maintenance doses of E3 (once or twice weekly) after initial treatment.
Number of subjects: 40
Study 1508058 — intervention group
Group type: EXPERIMENTAL
Intervention: Visual assessment method for vaginal epithelium maturation.
Number of subjects: 40
Study 1508058 — intervention group
Group type: EXPERIMENTAL
Intervention: E3 treatment.
Number of subjects: 40
Study 6579633 — intervention group
Group type: EXPERIMENTAL
Intervention: sucralfate 1 g bd
Number of subjects: 54
Study 6579633 — intervention group
Group type: EXPERIMENTAL
Intervention: sucralfate 1 g nocte
Number of subjects: 54
Study 6579633 — intervention group
Group type: COMPARATOR
Intervention: Control
Number of subjects: 54
Study 30870778 — intervention group
Group type: EXPERIMENTAL
Intervention: Whey protein supplementation (WP) with placebo (PLA)
Number of subjects: 70
Study 30870778 — intervention group
Group type: EXPERIMENTAL
Intervention: Placebo with whey protein (PLA-WP)
Number of subjects: 70
Study 30870778 — intervention group
Group type: COMPARATOR
Intervention: Placebo with placebo (PLA-PLA)
Number of subjects: 70
Study 29227052 — intervention group
Group type: EXPERIMENTAL
Intervention: Diagnostic laparoscopy (Group A)
Number of subjects: 58
Study 29227052 — intervention group
Group type: COMPARATOR
Intervention: Clinical and radiological follow-up (Group B)
Number of subjects: 58
Study 24166937 — intervention group
Group type: EXPERIMENTAL
Intervention: Narrative therapy
Number of subjects: 0
Study 24166937 — intervention group
Group type: COMPARATOR
Intervention: Cognitive-behavioral therapy
Number of subjects: 0
Study 24166937 — intervention group
Group type: EXPERIMENTAL
Intervention: Both treatments
Number of subjects: 0
Study 24118972 — intervention group
Group type: EXPERIMENTAL
Intervention: Once daily PTNS
Number of subjects: 30
Study 24118972 — intervention group
Group type: COMPARATOR
Intervention: Twice weekly PTNS
Number of subjects: 30
Study 21658527 — intervention group
Group type: EXPERIMENTAL
Intervention: Parental Friendship Coaching (PFC) delivered in eight, 90-minute sessions
Number of subjects: 32
Study 21658527 — intervention group
Group type: COMPARATOR
Intervention: Control group not specified
Number of subjects: 32
Study 18572266 — intervention group
Group type: EXPERIMENTAL
Intervention: liposomal doxorubicin
Number of subjects: 80
Study 18572266 — intervention group
Group type: COMPARATOR
Intervention: standard epirubicin
Number of subjects: 80
Study 16710750 — intervention group
Group type: EXPERIMENTAL
Intervention: Long schedule; estrogen began on the first day of menstruation
Number of subjects: 20
Study 16710750 — intervention group
Group type: COMPARATOR
Intervention: Standard schedule; estrogen began on the day of planned egg retrieval
Number of subjects: 20
Study 15204160 — intervention group
Group type: EXPERIMENTAL
Intervention: Calcipotriol cream plus PUVA therapy
Number of subjects: 120
Study 15204160 — intervention group
Group type: COMPARATOR
Intervention: Vehicle (placebo) plus PUVA therapy
Number of subjects: 120
Study 11264634 — intervention group
Group type: EXPERIMENTAL
Intervention: Clotrimazole (10 mg troche, three times daily)
Number of subjects: 35
Study 11264634 — intervention group
Group type: COMPARATOR
Intervention: Nystatin (5 mL oral suspension, four times daily)
Number of subjects: 35
Study 8319838 — intervention group
Group type: EXPERIMENTAL
Intervention: Nifedipine (20 mg, 3 times at 8-hour intervals on the day of ERCP +/− EST)
Number of subjects: 166
Study 8319838 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 166
Study 8319838 — intervention group
Group type: EXPERIMENTAL
Intervention: Nifedipine
Number of subjects: 166
Study 8319838 — intervention group
Group type: EXPERIMENTAL
Intervention: Nifedipine and Placebo
Number of subjects: 166
Study 3729097 — intervention group
Group type: EXPERIMENTAL
Intervention: Guidewire catheterization (GW)
Number of subjects: 210
Study 3729097 — intervention group
Group type: COMPARATOR
Intervention: Nonguidewire catheterization (NGW)
Number of subjects: 210
Study 29920778 — intervention group
Group type: EXPERIMENTAL
Intervention: Implant-supported removable partial dental prostheses (ISRPDPs) on the reconstructed side (Side R)
Number of subjects: 10
Study 29920778 — intervention group
Group type: COMPARATOR
Intervention: Control side (Side N)
Number of subjects: 10
Study 26673560 — intervention group
Group type: EXPERIMENTAL
Intervention: Rivaroxaban
Number of subjects: 13264
Study 26673560 — intervention group
Group type: COMPARATOR
Intervention: Warfarin
Number of subjects: 13264
Study 26673560 — intervention group
Group type: EXPERIMENTAL
Intervention: Polypharmacy (≥ 10 medications)
Number of subjects: 13264
Study 23543358 — intervention group
Group type: EXPERIMENTAL
Intervention: Educator-implemented intervention (reading storybooks and conducting stimulation activities)
Number of subjects: 222
Study 23543358 — intervention group
Group type: EXPERIMENTAL
Intervention: Educator-implemented intervention (with reliable implementation)
Number of subjects: 222
Study 23543358 — intervention group
Group type: COMPARATOR
Intervention: Control condition (no specific intervention)
Number of subjects: 222
Study 22084412 — intervention group
Group type: EXPERIMENTAL
Intervention: 20 mg enoxaparin
Number of subjects: 11794
Study 22084412 — intervention group
Group type: EXPERIMENTAL
Intervention: 40 mg enoxaparin
Number of subjects: 11794
Study 22084412 — intervention group
Group type: EXPERIMENTAL
Intervention: enoxaparin (20 mg or 40 mg)
Number of subjects: 11794
Study 20845216 — intervention group
Group type: EXPERIMENTAL
Intervention: 20-min ice-bag application
Number of subjects: 7
Study 20845216 — intervention group
Group type: EXPERIMENTAL
Intervention: 60-min gel-pack application at 10 degrees C
Number of subjects: 7
Study 20845216 — intervention group
Group type: EXPERIMENTAL
Intervention: 60-min gel-pack application at 17 degrees C
Number of subjects: 7
Study 20845216 — intervention group
Group type: COMPARATOR
Intervention: non-cooling treatment
Number of subjects: 7
Study 18664560 — intervention group
Group type: EXPERIMENTAL
Intervention: Clodronate 1600 mg/day for 2 years
Number of subjects: 290
Study 18664560 — intervention group
Group type: COMPARATOR
Intervention: No treatment (Control)
Number of subjects: 290
Study 15856335 — intervention group
Group type: EXPERIMENTAL
Intervention: Progressive muscle relaxation training (PMRT) and guided imagery (GI)
Number of subjects: 30
Study 15856335 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 30
Study 12719503 — intervention group
Group type: EXPERIMENTAL
Intervention: Nurse-administered Structured Clinical Interview for DSM-IV-Clinician Version (SCID)
Number of subjects: 296
Study 12719503 — intervention group
Group type: COMPARATOR
Intervention: Control condition (no SCID)
Number of subjects: 296
Study 10554388 — intervention group
Group type: EXPERIMENTAL
Intervention: Waking-alert procedure
Number of subjects: 80
Study 10554388 — intervention group
Group type: COMPARATOR
Intervention: Active-alert procedure
Number of subjects: 80
Study 7490838 — intervention group
Group type: EXPERIMENTAL
Intervention: 8 months of reversible androgen ablation therapy
Number of subjects: 50
Study 1586932 — intervention group
Group type: EXPERIMENTAL
Intervention: Enalapril (3 months therapy)
Number of subjects: 12
Study 1586932 — intervention group
Group type: COMPARATOR
Intervention: Sclerotherapy and placebo (control group)
Number of subjects: 12
Study 3156909 — intervention group
Group type: EXPERIMENTAL
Intervention: R011-1163
Number of subjects: 25
Study 3156909 — intervention group
Group type: EXPERIMENTAL
Intervention: Amitriptyline
Number of subjects: 25
Study 31354243 — intervention group
Group type: EXPERIMENTAL
Intervention: Duloxetine
Number of subjects: 104
Study 31354243 — intervention group
Group type: EXPERIMENTAL
Intervention: Gabapentin
Number of subjects: 104
Study 28787243 — intervention group
Group type: EXPERIMENTAL
Intervention: High-Intensity Training (HIT, n=31)
Number of subjects: 62
Study 28787243 — intervention group
Group type: COMPARATOR
Intervention: Low-Intensity Training (LIT, n=31)
Number of subjects: 62
Study 27388281 — intervention group
Group type: EXPERIMENTAL
Intervention: Tranexamic acid (TXA)
Number of subjects: 28
Study 27388281 — intervention group
Group type: COMPARATOR
Intervention: Normal saline (placebo)
Number of subjects: 28
Study 25496504 — intervention group
Group type: EXPERIMENTAL
Intervention: Inhaled PGE1 (IPGE1) at low dose (150 ng/kg/min)
Number of subjects: 7
Study 25496504 — intervention group
Group type: EXPERIMENTAL
Intervention: Inhaled PGE1 (IPGE1) at high dose (300 ng/kg/min)
Number of subjects: 7
Study 25496504 — intervention group
Group type: COMPARATOR
Intervention: Aerosolized saline (control)
Number of subjects: 7
Study 25496504 — intervention group
Group type: EXPERIMENTAL
Intervention: Overall recruitment
Number of subjects: 7
Study 25496504 — intervention group
Group type: EXPERIMENTAL
Intervention: Primary outcome of enrollment
Number of subjects: 7
Study 25496504 — intervention group
Group type: EXPERIMENTAL
Intervention: Adverse events
Number of subjects: 7
Study 22800625 — intervention group
Group type: EXPERIMENTAL
Intervention: Delayed clamping (1 min after delivery)
Number of subjects: 158
Study 22800625 — intervention group
Group type: COMPARATOR
Intervention: Early clamping (< 15 s after delivery)
Number of subjects: 158
Study 20410252 — intervention group
Group type: EXPERIMENTAL
Intervention: Additional psychological treatment (written information on medical and psychological consequences of an ICD plus 6 months of individual phone counseling)
Number of subjects: 119
Study 20410252 — intervention group
Group type: COMPARATOR
Intervention: Usual medical aftercare
Number of subjects: 119
Study 20410252 — intervention group
Group type: EXPERIMENTAL
Intervention: Additional psychological treatment
Number of subjects: 119
Study 20410252 — intervention group
Group type: EXPERIMENTAL
Intervention: All patients (ICD patients)
Number of subjects: 119
Study 18509656 — intervention group
Group type: EXPERIMENTAL
Intervention: Group A: 100 mL of 300 mg I/mL at 5.0 mL/s
Number of subjects: 80
Study 18509656 — intervention group
Group type: EXPERIMENTAL
Intervention: Group B: 100 mL of 350 mg I/mL at 5.0 mL/s
Number of subjects: 80
Study 18509656 — intervention group
Group type: EXPERIMENTAL
Intervention: Group C: 100 mL of 300 mg I/mL at 3.5 mL/s
Number of subjects: 80
Study 18509656 — intervention group
Group type: EXPERIMENTAL
Intervention: Group D: 100 mL of 350 mg I/mL at 3.5 mL/s
Number of subjects: 80
Study 15861762 — intervention group
Group type: EXPERIMENTAL
Intervention: Instillation of water for 15 minutes before syringing
Number of subjects: 26
Study 15861762 — intervention group
Group type: COMPARATOR
Intervention: Immediate syringing
Number of subjects: 26
Study 12204703 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.005% latanoprost once daily (n = 737)
Number of subjects: 1389
Study 12204703 — intervention group
Group type: COMPARATOR
Intervention: 0.5% timolol twice daily (n = 652)
Number of subjects: 1389
Study 10480616 — intervention group
Group type: EXPERIMENTAL
Intervention: Acipimox (250 mg)
Number of subjects: 43
Study 10480616 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 43
Study 8739541 — intervention group
Group type: EXPERIMENTAL
Intervention: Pentoxifylline 600 mg intravenously twice a day
Number of subjects: 114
Study 8739541 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 114
Study 1607532 — intervention group
Group type: EXPERIMENTAL
Intervention: 100 mg/2 h of rt‐PA (Activase)
Number of subjects: 90
Study 1607532 — intervention group
Group type: COMPARATOR
Intervention: 3 million U/2 h of urokinase (Abbokinase)
Number of subjects: 90
Study 1607532 — intervention group
Group type: EXPERIMENTAL
Intervention: Both treatments
Number of subjects: 90
Study 6242148 — intervention group
Group type: EXPERIMENTAL
Intervention: 2 micrograms subcutaneously
Number of subjects: 197
Study 6242148 — intervention group
Group type: EXPERIMENTAL
Intervention: 2 micrograms intradermally
Number of subjects: 197
Study 6242148 — intervention group
Group type: COMPARATOR
Intervention: Hevac B (placebo-treated carriers)
Number of subjects: 197
Study 6242148 — intervention group
Group type: EXPERIMENTAL
Intervention: Booster vaccination of initial non‐responders
Number of subjects: 197
Study 30886069 — intervention group
Group type: EXPERIMENTAL
Intervention: Proximal ultrasound-guided GON block with bupivacaine and methylprednisolone acetate
Number of subjects: 40
Study 30886069 — intervention group
Group type: EXPERIMENTAL
Intervention: Distal ultrasound-guided GON block with bupivacaine and methylprednisolone acetate
Number of subjects: 40
Study 30886069 — intervention group
Group type: EXPERIMENTAL
Intervention: Proximal ultrasound-guided GON block
Number of subjects: 40
Study 30886069 — intervention group
Group type: EXPERIMENTAL
Intervention: Distal ultrasound-guided GON block
Number of subjects: 40
Study 30886069 — intervention group
Group type: COMPARATOR
Intervention: Both techniques
Number of subjects: 40
Study 29724165 — intervention group
Group type: EXPERIMENTAL
Intervention: Twice-weekly supervised exercise sessions and nutritional counselling (n=303)
Number of subjects: 589
Study 29724165 — intervention group
Group type: COMPARATOR
Intervention: Standard prenatal care (n=303)
Number of subjects: 589
Study 26438574 — intervention group
Group type: COMPARATOR
Intervention: 4-valent HPV vaccination program
Number of subjects: 2
Study 26438574 — intervention group
Group type: EXPERIMENTAL
Intervention: 9-valent HPV vaccination program
Number of subjects: 2
Study 26438574 — intervention group
Group type: EXPERIMENTAL
Intervention: Switching to a 9-valent gender-neutral program
Number of subjects: 2
Study 25208688 — intervention group
Group type: EXPERIMENTAL
Intervention: SMART™ CONTROL stent
Number of subjects: 346
Study 25208688 — intervention group
Group type: EXPERIMENTAL
Intervention: COMPLETE™‐SE stent
Number of subjects: 346
Study 25208688 — intervention group
Group type: EXPERIMENTAL
Intervention: Aspirin plus clopidogrel
Number of subjects: 346
Study 25208688 — intervention group
Group type: COMPARATOR
Intervention: Aspirin plus cilostazol
Number of subjects: 346
Study 21811291 — intervention group
Group type: COMPARATOR
Intervention: Control low-fat milk
Number of subjects: 13
Study 21811291 — intervention group
Group type: EXPERIMENTAL
Intervention: Cream
Number of subjects: 13
Study 21811291 — intervention group
Group type: EXPERIMENTAL
Intervention: Butter
Number of subjects: 13
Study 21811291 — intervention group
Group type: EXPERIMENTAL
Intervention: Cheese
Number of subjects: 13
Study 21811291 — intervention group
Group type: EXPERIMENTAL
Intervention: Yoghurt
Number of subjects: 13
Study 21811291 — intervention group
Group type: EXPERIMENTAL
Intervention: Non-fermented dairy diet (butter, cream, ice cream)
Number of subjects: 13
Study 21811291 — intervention group
Group type: EXPERIMENTAL
Intervention: Fermented dairy diet (cheese, yoghurt)
Number of subjects: 13
Study 20184573 — intervention group
Group type: EXPERIMENTAL
Intervention: TURP
Number of subjects: 150
Study 20184573 — intervention group
Group type: EXPERIMENTAL
Intervention: CLP
Number of subjects: 150
Study 20184573 — intervention group
Group type: EXPERIMENTAL
Intervention: EVAP
Number of subjects: 150
Study 20184573 — intervention group
Group type: COMPARATOR
Intervention: TURP, CLP, EVAP
Number of subjects: 150
Study 17949573 — intervention group
Group type: EXPERIMENTAL
Intervention: Clinical practice guideline treatment by trained family doctors
Number of subjects: 419
Study 17949573 — intervention group
Group type: COMPARATOR
Intervention: Control group treatment by family doctors unaware of the guideline
Number of subjects: 419
Study 17949573 — intervention group
Group type: EXPERIMENTAL
Intervention: Clinical practice guideline treatment
Number of subjects: 419
Study 17949573 — intervention group
Group type: COMPARATOR
Intervention: Control group treatment
Number of subjects: 419
Study 16112646 — intervention group
Group type: EXPERIMENTAL
Intervention: Testis cDNA library immunoscreening with sera from AML patients
Number of subjects: 0
Study 16112646 — intervention group
Group type: EXPERIMENTAL
Intervention: RT-PCR analysis
Number of subjects: 0
Study 16112646 — intervention group
Group type: EXPERIMENTAL
Intervention: Real-time PCR (RQ-PCR)
Number of subjects: 0
Study 16112646 — intervention group
Group type: EXPERIMENTAL
Intervention: Antigen presentation assays using mo-DCs
Number of subjects: 0
Study 11866684 — intervention group
Group type: EXPERIMENTAL
Intervention: Clopidogrel plus aspirin (loading dose of 300 mg p.o. followed by 75 mg/day; aspirin 75-325 mg/day)
Number of subjects: 0
Study 11866684 — intervention group
Group type: COMPARATOR
Intervention: Aspirin alone (control group)
Number of subjects: 0
Study 11866684 — intervention group
Group type: EXPERIMENTAL
Intervention: Clopidogrel plus aspirin
Number of subjects: 0
Study 10228050 — intervention group
Group type: EXPERIMENTAL
Intervention: Hepatitis B vaccination
Number of subjects: 805
Study 7676769 — intervention group
Group type: EXPERIMENTAL
Intervention: Amicar
Number of subjects: 30
Study 7676769 — intervention group
Group type: COMPARATOR
Intervention: Control (no Amicar)
Number of subjects: 30
Study 2345255 — intervention group
Group type: EXPERIMENTAL
Intervention: multivitamin
Number of subjects: 90
Study 2345255 — intervention group
Group type: EXPERIMENTAL
Intervention: multivitamin and iron
Number of subjects: 90
Study 2345255 — intervention group
Group type: EXPERIMENTAL
Intervention: multivitamin, iron, and zinc
Number of subjects: 90
Study 2345255 — intervention group
Group type: EXPERIMENTAL
Intervention: multivitamin and zinc
Number of subjects: 90
Study 2345255 — intervention group
Group type: COMPARATOR
Intervention: placebo
Number of subjects: 90
Study 7179191 — intervention group
Group type: EXPERIMENTAL
Intervention: Naftidrofuryl
Number of subjects: 11
Study 7179191 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 11
Study 31818675 — intervention group
Group type: EXPERIMENTAL
Intervention: Intermittent energy restriction (IER)
Number of subjects: 186
Study 31818675 — intervention group
Group type: COMPARATOR
Intervention: Continuous energy restriction (CER)
Number of subjects: 186
Study 29901484 — intervention group
Group type: EXPERIMENTAL
Intervention: Health Belief Model Comprehensive Reminder System
Number of subjects: 174
Study 29901484 — intervention group
Group type: COMPARATOR
Intervention: Control (not specified)
Number of subjects: 174
Study 26487303 — intervention group
Group type: EXPERIMENTAL
Intervention: Desflurane (3-6%)
Number of subjects: 52
Study 26487303 — intervention group
Group type: COMPARATOR
Intervention: Sevoflurane (1-2%)
Number of subjects: 52
Study 25190661 — intervention group
Group type: EXPERIMENTAL
Intervention: Scleral contact lenses with a thick postlens tear layer (Tpost‐tear 350 μm)
Number of subjects: 8
Study 22357255 — intervention group
Group type: EXPERIMENTAL
Intervention: Nilotinib 400 mg b.i.d.
Number of subjects: 248
Study 22357255 — intervention group
Group type: COMPARATOR
Intervention: Best supportive care (BSC)
Number of subjects: 248
Study 20353107 — intervention group
Group type: EXPERIMENTAL
Intervention: Electroacupuncture; treated at Guanyuan (CV 4), Zhongji (CV 3), Ciliao (BL 32), and Huiyang (BL 35)
Number of subjects: 48
Study 20353107 — intervention group
Group type: COMPARATOR
Intervention: Western medicine (Sparfloxacin tablets and Prostat tablets); oral administration
Number of subjects: 48
Study 17361125 — intervention group
Group type: EXPERIMENTAL
Intervention: Lansoprazole
Number of subjects: 3
Study 17361125 — intervention group
Group type: EXPERIMENTAL
Intervention: Rifampin
Number of subjects: 3
Study 15841494 — intervention group
Group type: EXPERIMENTAL
Intervention: Mobicox (meloxicam 7.5 mg)
Number of subjects: 23
Study 15841494 — intervention group
Group type: EXPERIMENTAL
Intervention: Promotion (meloxicam 7.5 mg)
Number of subjects: 23
Study 15841494 — intervention group
Group type: COMPARATOR
Intervention: Both formulations (Mobicox and Promotion)
Number of subjects: 23
Study 11926718 — intervention group
Group type: EXPERIMENTAL
Intervention: Fluoxetine (20 to 80 mg/day)
Number of subjects: 301
Study 11926718 — intervention group
Group type: EXPERIMENTAL
Intervention: Fluoxetine
Number of subjects: 301
Study 11926718 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 301
Study 9816522 — intervention group
Group type: EXPERIMENTAL
Intervention: Intracoronary brachytherapy with 32P beta-emitter at doses of 16, 20, and 24 Gy
Number of subjects: 0
Study 7630516 — intervention group
Group type: EXPERIMENTAL
Intervention: bromocriptine + FSH + HMG (Group A)
Number of subjects: 28
Study 7630516 — intervention group
Group type: COMPARATOR
Intervention: goserelin depot (Zoladex) + HMG (Group B)
Number of subjects: 28
Study 2744187 — intervention group
Group type: EXPERIMENTAL
Intervention: Bromocriptine therapy
Number of subjects: 35
Study 359925 — intervention group
Group type: EXPERIMENTAL
Intervention: 300 mg of Rifampicin daily for 3 months
Number of subjects: 24
Study 359925 — intervention group
Group type: COMPARATOR
Intervention: 50 mg D.D.S. daily for 3 months
Number of subjects: 24
Study 31322024 — intervention group
Group type: EXPERIMENTAL
Intervention: Muscle Training and Exercise (MTE)
Number of subjects: 0
Study 31322024 — intervention group
Group type: COMPARATOR
Intervention: Adapting Alignment Exercise (AAE)
Number of subjects: 0
Study 30919998 — intervention group
Group type: EXPERIMENTAL
Intervention: EA-230 (15, 45 and 90 mg/kg/h)
Number of subjects: 36
Study 30919998 — intervention group
Group type: EXPERIMENTAL
Intervention: EA-230 (90 mg/kg/h)
Number of subjects: 36
Study 30919998 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 36